Trial Information - Phase III
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
Protocol ID: 849-010
Sponsor: Mirati Therapeutics Inc.
Status: PENDING STAR
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
